Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation | Zendy

Yasutomo Teshima | Zendy; Minako Kizaki | Zendy; Ryohei Kurihara | Zendy; Ryosuke Kano | Zendy; Miki Harumiya | Zendy

Open Access

Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation

Author(s) -

Yasutomo Teshima,

Minako Kizaki,

Ryohei Kurihara,

Ryosuke Kano,

Miki Harumiya

Publication year - 2020

Publication title -

international journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.06

H-Index - 62

eISSN - 1437-7772

pISSN - 1341-9625

DOI - 10.1007/s10147-020-01737-3

Subject(s) - medicine , dabrafenib , trametinib , rash , oncology , melanoma , adverse effect , vemurafenib , interim analysis , gastroenterology , surgery , clinical trial , metastatic melanoma , cancer , cancer research , kinase , mapk/erk pathway , biology , microbiology and biotechnology

To investigate the safety and efficacy of dabrafenib and trametinib combination therapy for BRAF V600 mutation-positive unresectable and metastatic melanoma in over 100 Japanese patients of a real-world clinical setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research